Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs

Like security screening to make sure nothing harmful makes its way into a crowded area, cells in the human body use checkpoints to control their growth and prevent harmful mutations from making their way into new cell populations and causing trouble.

Every cell that divides and replicates its DNA must clear at least three checkpoints - all of which call on specialised genes known as tumour suppressors.

Tumour suppressor genes encode proteins that work with other molecules in cells to put the brakes on cell division when DNA damage or other defects are detected.

This process prevents mutations that harm cells or that lead to uncontrolled cell growth and cancer from being passed along to new cells.

Fortunately, tumour suppressors are fairly robust.

Under normal circumstances, they stop working only when mutations affect both of the tumour suppressor gene's alleles, which are the different forms of a gene inherited from each parent.

But in the case of prostate cancer, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) and Fox Chase Cancer Center recently discovered an important exception to this two mutation rule.

Working in human cells and animal models, they found that a mutation leading to the loss of just one allele of a tumour suppressor gene known as PPP2R2A is enough to make a tumour caused by other mutations worse.

In a study published in the journal Oncogenesis, the team, led by Xavier Graña, PhD, Professor of Medical Genetics and Molecular Biochemistry, and in the Fels Institute for Cancer Research and Molecular Biology at LKSOM, found that patients whose prostate tumours carry only one copy of PPP2R2A do not survive as long as those whose tumours have two copies of the gene.

They also showed that in cells deficient in PPP2R2A, reconstitution of the PP2A protein encoded by the gene ultimately kills prostate cancer cells.

The study is the first to show that reactivating PP2A in affected cells can slow or stop the advance of prostate cancer in an animal model.

"The majority of prostate tumours have only one functional copy of the PPP2R2A gene," Dr. Graña explained. "Because this alteration occurs so frequently, many patients could benefit from treatments that restore the gene's activity."

Dr. Graña's team mapped out specifically what happens when cells lose a copy of PPP2R2A, and what happens when PP2A is reconstituted.

When lost, they found that cells were more likely to divide and replicate, thereby generating more cells - a process that fuels cancer progression.

This occurred because cells just breezed through the so-called mitotic checkpoint, which normally ensures that a cell's chromosomes are organised properly for cell division.

PP2A reactivation, on the other hand, resulted in sustained activation of the mitotic checkpoint - to the point that the cellular machinery responsible for separating replicated chromosomes for division collapsed, killing the cells.

"Restoring PP2A to normal levels in these cancer cells caused a weakening of their centrosome, which is the organiser of the cell machinery in charge of faithfully separating chromosomes," Dr. Graña explained. "The combination of a sustained checkpoint and a weakened centrosome results in collapse of the mitotic apparatus, with chromosomes not knowing where they have to go."

"Our findings indicate that prostate tumours often kick off a copy of the PPP2R2A gene to facilitate their growth and that bringing PP2A levels back to normal results in abnormal chromosome sorting and cell death."

Small molecules that activate PP2A and that have the potential to be developed into drugs have already been identified.

Whether they specifically activate PP2A in prostate cancer remains unclear, however.

"More work is needed to find a specific drug for this complex, but we have a promising start," Dr. Graña added.

Source: Temple University Health System

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation